Absci Announces Research Collaboration With Merck

Absci Corporation, the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, announced that it has entered into a research collaboration with Merck, known as MSD outside of the United States and Canada, using Absci’s AI-powered Integrated Drug Creation™ Platform.